Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
15.38
-0.22 (-1.44%)
Aug 14, 2025, 11:16 AM - Market open

Rapport Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
Net Income
-88.31-78.31-34.79-11.62
Depreciation & Amortization
0.980.840.110.02
Asset Writedown & Restructuring Costs
---5.45
Loss (Gain) From Sale of Investments
-1.93-3.21-0.08-
Stock-Based Compensation
14.8210.243.530.61
Other Operating Activities
1.228.031.390.38
Change in Accounts Payable
1.91-0.350.861.58
Change in Other Net Operating Assets
-4.85-2.071.80.05
Operating Cash Flow
-76.17-64.83-27.18-3.54
Capital Expenditures
-0.68-2.41-1.64-0.31
Sale (Purchase) of Intangibles
----5.45
Investment in Securities
23.2-167.74-77.22-
Investing Cash Flow
22.52-170.14-78.86-5.76
Total Debt Issued
---8.73
Net Debt Issued (Repaid)
---8.73
Issuance of Common Stock
-157.710.050.03
Repurchase of Common Stock
-1.38--0-
Other Financing Activities
-0.06--0.13-0.11
Financing Cash Flow
-1.45221.63145.1443.29
Net Cash Flow
-55.1-13.3439.133.99
Free Cash Flow
-76.85-67.23-28.82-3.85
Free Cash Flow Per Share
-2.18-3.24-19.14-4.95
Levered Free Cash Flow
-51.03-44.47-17.43-
Unlevered Free Cash Flow
-51.03-44.47-17.43-
Change in Working Capital
-2.94-2.422.651.62
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q